SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Indoco Remedies rises on getting EIR from USFDA for API manufacturing facility at Patalganga

12 Dec 2025 Evaluate

Indoco Remedies is currently trading at Rs. 241.05, up by 1.65 points or 0.69% from its previous closing of Rs. 239.40 on the BSE.

The scrip opened at Rs. 240.00 and has touched a high and low of Rs. 251.05 and Rs. 239.25 respectively. So far 1433 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 2 has touched a 52 week high of Rs. 348.60 on 17-Dec-2024 and a 52 week low of Rs. 190.00 on 28-Feb-2025.

Last one week high and low of the scrip stood at Rs. 254.70 and Rs. 236.05 respectively. The current market cap of the company is Rs. 2223.64 crore.

The promoters holding in the company stood at 58.90%, while Institutions and Non-Institutions held 19.41% and 21.69% respectively.

Indoco Remedies has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) for its Active Pharmaceutical Ingredients (API) manufacturing facility located at Patalganga, following a successful Inspection of the said facility from September 15, 2025 to September 19, 2025.

Indoco Remedies is engaged in the manufacturing and marketing of formulations (finished dosage forms) and active pharmaceutical ingredients (APIs) in India.

Indoco Remedies Share Price

209.95 7.80 (3.86%)
13-Apr-2026 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1652.00
Dr. Reddys Lab 1235.00
Cipla 1211.30
Zydus Lifesciences 920.00
Lupin 2316.10
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×